James M.  Daly net worth and biography

James Daly Biography and Net Worth

Mr. Daly brings more than 30 years of experience leading U.S. and global pharmaceutical businesses to the Board of Directors. He retired from Incyte Corporation, a biopharmaceutical company, where he served as Executive Vice President and Chief Commercial Officer from October 2012 to June 2015. Prior to Incyte, Mr. Daly served in various senior management and commercial positions at Amgen, Inc., a global pharmaceutical company, from January 2002 to December 2011. Prior to Amgen, he worked at GlaxoSmisthKline from 1985 to 2001 in various positions of increasing responsibilities. Mr. Daly serves on the board of directors of Acadia Pharmaceuticals, Inc., argenx SE, Bellicum Pharmaceuticals, Inc., and Madrigal Pharmaceuticals, Inc. Mr. Daly earned a BS degree in Pharmacy and his MBA from the University at Buffalo. Mr. Daly serves on the Nominating and Corporate Governance Committee and the Audit Committee.

What is James M. Daly's net worth?

The estimated net worth of James M. Daly is at least $60,223.46 as of April 1st, 2024. Mr. Daly owns 1,198 shares of Halozyme Therapeutics stock worth more than $60,223 as of June 19th. This net worth estimate does not reflect any other investments that Mr. Daly may own. Learn More about James M. Daly's net worth.

How do I contact James M. Daly?

The corporate mailing address for Mr. Daly and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on James M. Daly's contact information.

Has James M. Daly been buying or selling shares of Halozyme Therapeutics?

James M. Daly has not been actively trading shares of Halozyme Therapeutics in the last ninety days. Most recently, James M. Daly sold 10,000 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $43.74, for a transaction totalling $437,400.00. Following the completion of the sale, the director now directly owns 20,503 shares of the company's stock, valued at $896,801.22. Learn More on James M. Daly's trading history.

Who are Halozyme Therapeutics' active insiders?

Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.

Are insiders buying or selling shares of Halozyme Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 180,000 shares worth more than $7,501,100.00. The most recent insider tranaction occured on June, 11th when Director Matthew L Posard sold 10,000 shares worth more than $500,100.00. Insiders at Halozyme Therapeutics own 2.7% of the company. Learn More about insider trades at Halozyme Therapeutics.

Information on this page was last updated on 6/11/2024.

James M. Daly Insider Trading History at Halozyme Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2023Sell10,000$43.74$437,400.0020,503View SEC Filing Icon  
8/11/2023Sell10,000$43.71$437,100.0030,503View SEC Filing Icon  
8/13/2020Sell34,337$29.12$999,893.4431,365View SEC Filing Icon  
See Full Table

James M. Daly Buying and Selling Activity at Halozyme Therapeutics

This chart shows James M Daly's buying and selling at Halozyme Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Halozyme Therapeutics Company Overview

Halozyme Therapeutics logo
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $50.27
Low: $49.00
High: $50.84

50 Day Range

MA: $43.22
Low: $37.81
High: $51.44

2 Week Range

Now: $50.27
Low: $32.83
High: $53.00

Volume

1,035,344 shs

Average Volume

1,305,459 shs

Market Capitalization

$6.40 billion

P/E Ratio

20.77

Dividend Yield

N/A

Beta

1.28